Gilead Sciences, Inc. (FRA:GIS)

Germany flag Germany · Delayed Price · Currency is EUR
96.13
+0.93 (0.98%)
At close: Sep 29, 2025
0.98%
Market Cap119.11B
Revenue (ttm)24.58B
Net Income (ttm)5.37B
Shares Outn/a
EPS (ttm)4.27
PE Ratio22.17
Forward PE13.33
Dividend2.82 (2.93%)
Ex-Dividend DateSep 15, 2025
Volume86
Average Volume246
Open95.51
Previous Close95.20
Day's Range95.51 - 96.13
52-Week Range73.77 - 111.04
Betan/a
RSI47.22
Earnings DateNov 6, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 17,600
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol GIS
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

May 2026 Options Now Available For Gilead Sciences (GILD)

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading today, for the May 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay,...

12 days ago - Nasdaq

Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management

SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Scie...

13 days ago - Wallstreet:Online

Fangzhou Wins Gilead ‘Award of Excellence' for AI-Driven Chronic Disease Management

SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Scie...

13 days ago - GlobeNewsWire

GILD Partners with Nurix for Potential IRAK4 Protein Degrader

GILD Partners with Nurix for Potential IRAK4 Protein Degrader

13 days ago - GuruFocus

Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences Inc (GILD)

Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences Inc (GILD)

14 days ago - GuruFocus

QQQM, GOOGL, ADBE, GILD: Large Inflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco NASDAQ 100 ETF (Symbol: QQQM) where we have detected an approx...

14 days ago - Nasdaq

GILD: JP Morgan Raises Price Target, Reaffirms Overweight Rating | GILD Stock News

GILD: JP Morgan Raises Price Target, Reaffirms Overweight Rating | GILD Stock News

14 days ago - GuruFocus

Validea Detailed Fundamental Analysis - GILD

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published strateg...

15 days ago - Nasdaq

Notable Friday Option Activity: GSHD, GILD, EOSE

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Goosehead Insurance Inc (Symbol: GSHD), where a total of 2,556 contracts have traded so far...

18 days ago - Nasdaq

VEEV Partners with Gilead Sciences to Enhance CRM with AI

VEEV Partners with Gilead Sciences to Enhance CRM with AI

20 days ago - GuruFocus

Gilead a safe option for investors: Seigerman

Evan Seigerman, managing director at BioPharma Equity Research, joins BNN Bloomberg to share his Hot Picks in pharma.

25 days ago - BNN Bloomberg

Gilead (GILD) Partners with Global Fund for HIV Prevention Initiative

Gilead (GILD) Partners with Global Fund for HIV Prevention Initiative

25 days ago - GuruFocus

Gilead Sciences (GILD) Teams Up with U.S. to Expand Lenacapavir Access

Gilead Sciences (GILD) Teams Up with U.S. to Expand Lenacapavir Access

26 days ago - GuruFocus

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention ...

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries | GILD Stock News

26 days ago - GuruFocus

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilea...

26 days ago - Wallstreet:Online

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief...

26 days ago - Business Wire

US plans to bring Gilead HIV drug to market in high-burden HIV countries

The U.S. State Department announced a plan on Thursday to bring Gilead Sciences Inc's drug lenacapavir to market "at cost" in high-burden HIV countries in an effort to reach 2 million people over thre...

26 days ago - Reuters

Gilead Sciences, Inc. (GILD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Gilead Sciences highlights strong growth, successful Yeztugo HIV prevention launch, and

26 days ago - Seeking Alpha

Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U, a new campaign that spotlights the multifaceted experiences of people living with HIV globally. The timing of the campaign ...

26 days ago - Wallstreet:Online

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U™, a new campaign that spotlights the multifaceted experiences of people living with HI...

26 days ago - Business Wire